Best Practice & Research Clinical Haematology

Papers
(The median citation count of Best Practice & Research Clinical Haematology is 1. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-04-01 to 2025-04-01.)
ArticleCitations
CARs for lymphoma46
How do molecular aberrations guide therapy in MDS?26
Prevention and treatment of COVID-19 in patients with benign and malignant blood disorders21
Myeloproliferative neoplasms in adolescents and young adults19
Should all CAR-T therapy for acute lymphoblastic leukemia Be consolidated with allogeneic stem cell transplant?17
Addressing symptom burden in myeloproliferative neoplasms17
Preface of special edition “Biostatistics in clinical haematology”15
Late effects and frontline treatment selection for children with non-Hodgkin lymphoma14
Diagnosis and management of rare paediatric Non-Hodgkin lymphoma14
Donor lymphocyte infusion in Acute Myeloid Leukemia14
Diagnosis and management of ALK-positive anaplastic large cell lymphoma in children and adolescents14
Diagnosis and management of mature B-cell lymphomas in children, adolescents, and young adults14
From clones to immunopeptidomes: New developments in the characterization of permissive HLA-DP mismatches in hematopoietic cell transplantation13
Marrow failure and aging: The role of “Inflammaging”13
Editorial Board12
Cytomegalovirus in haematopoietic cell transplantation - The troll is still there12
Considerations to comprehensive care for the older individual with myelofibrosis11
Worldwide sources of data in haematology: Importance of clinician-biostatistician collaboration11
Contemporary and future strategies in polycythemia vera10
Changing trends in the therapy of acute myeloid leukemia10
Mechanisms of resistance to hypomethylating agents and BCL-2 inhibitors10
Mechanisms of thrombosis in pancreatic ductal adenocarcinoma10
Immunopathogenic mechanisms and modulatory approaches to graft-versus-host disease prevention in acute myeloid leukaemia9
The role of registries in hematological disorders9
Treatment of telomeropathies9
Shape of the art: TCR-repertoire after allogeneic hematopoietic cell transplantation8
The Australian Aplastic Anaemia and other Bone Marrow Failure Syndromes Registry8
HLA structure and function in hematopoietic-cell transplantation8
HLA typing: A review of methodologies and clinical impact on haematopoietic cell transplantation7
Providing hematopoietic stem cell products from unrelated donors to the world: DKMS donor centers and DKMS Registry7
The correlations among racial/ethnic groups, hypertriglyceridemia, thrombosis, and mortality in hospitalized patients with COVID-197
Is HLA-E with its receptors an immune checkpoint or an antigenic determinant in allo-HCT?7
Update on diagnostic approaches and therapeutic strategies in systemic mastocytosis7
Interfering with KIR and NKG2A immune checkpoint axes to unleash NK cell immunotherapy6
The role of randomized controlled trials, registries, observational databases in evaluating new interventions6
Clinical experience of CAR T cells for multiple myeloma6
Corrigendum to “HIV-associated lymphoma” [Best Pract Res Clin Haematol 25 (2012) 101–117]6
Effectiveness of allogeneic hematopoietic cell transplantation for older patients with acute myeloid leukemia6
Analyte heterogeneity analysis as a possible potency parameter for MSC5
“The state of the science” of childhood, adolescent and young adult Non Hodgkin Lymphoma (NHL)5
Cardio-oncology and transplantation for acute myeloid leukemia5
What are the long-term complications of pediatric ALL treatments and how can they be mitigated? Perspectives on long-term consequences of curative treatment in childhood ALL5
Cytokine therapy of acute radiation syndrome5
Asparaginase dosing for obese patients with acute lymphoblastic leukemia and factors that contribute to outcomes5
Redefining the biological basis of lineage-ambiguous leukemia through genomics: BCL11B deregulation in acute leukemias of ambiguous lineage5
Cellular and humoral immunotherapy in children, adolescents and young adults with non-Hodgkin lymphoma5
Transplantation algorithm for myelofibrosis in 2022 and beyond5
Editorial Board / Aims & Scope5
Bone marrow failure syndromes5
Since everyone has a donor, why are some eligible patients still not transplanted?5
Editorial Board / Aims & Scope5
WHO, what, when, where, and why: New classification systems for acute myeloid leukemia and their impact on clinical practice4
Mesenchymal stem cells in hematology: Therapeutic initiatives and future directions4
Best practice & research clinical haematology: Screening for breast cancer in hodgkin lymphoma survivors4
Reducing barriers of access and care related to hematopoietic cell transplantation and cellular therapy: The mission-driven role of the national marrow donor program4
Allogeneic “Off-the-Shelf” CAR T cells: Challenges and advances4
How predictive is the finding of clonal hematopoiesis for the development of myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML)?4
Coagulopathy in COVID-19 and anticoagulation clinical trials3
Distinguishing constitutional from acquired bone marrow failure in the hematology clinic3
Acute GVHD: New approaches to clinical trial monitoring3
Editorial Board / Aims & Scope3
Anti-GM-CSF autoantibodies in myeloid leukemias3
How can we design a better care model to address the acute distress of an acute leukemia diagnosis? Care models to address the acute distress of an acute leukemia diagnosis3
Hodgkin Lymphoma: A disease shaped by the tumor micro- and macroenvironment3
COVID-19 and antiphospholipid antibodies3
Editorial Board / Aims & Scope3
Endpoint selection and evaluation in hematology studies3
Human mesenchymal stem cell therapy: Potential advances for reducing cystic fibrosis infection and organ inflammation3
Diagnosis and management of cutaneous lymphomas and lymphoid proliferations in children, adolescents and young adults (CAYA)3
Handling missing covariate data in clinical studies in haematology3
The Collaborative Biobank (CoBi): Donor and recipient samples & data to facilitate future research on hematopoietic cell transplantation2
Celebrating the registration of 9.000 patients treated with CAR T cells in the EBMT registry: Collection of real-world data in the context of hematopoietic cellular therapies2
The presentation of results from studies in clinical haematology2
Treatment modalities in cancer-associated venous thromboembolism (VTE)2
Editorial Board / Aims & Scope2
Registries and observational databases in haematology2
Is there an optimal adjunct therapy to traditional cytotoxic induction?2
Advances in CAR design2
Take a spin: Apheresis in the care of adult leukaemia patients2
How can we intervene to mitigate post-transplantation relapse in AML? Strategies to mitigate post-transplantation relapse in AML2
Thrombosis and bleeding in hematological malignancy2
Challenges in anticoagulation for patients with brain tumors2
Allogeneic hematopoietic cell transplantation in acute myeloid leukemia1
Can venetoclax-based therapy replace 7+3 induction in fit older adults with AML?1
How can we improve response assessments in MDS? Strategies to improve response assessment in MDS treatment paradigms1
Cytogenetics and molecular genetics of myelodysplastic neoplasms1
Special issue 37.3: “Genetics and function of HLA and immune-related genes in hematopoietic cell transplantation and cellular immunotherapy”1
Dermatologic complications in transplantation and cellular therapy for acute leukemia1
Editorial Board / Aims & Scope1
Cytokines in hematopoietic cell transplantation and related cellular therapies1
Vaccine-induced immune thrombotic thrombocytopenia1
COVID-19 and HSCT (Hematopoietic stem cell transplant)1
What is the role of the bone marrow microenvironment in AML?1
Cytogenetics and genomics of acute myeloid leukemia1
The current landscape: Allogeneic hematopoietic stem cell transplant for acute lymphoblastic leukemia1
Thrombopoietin receptor agonists for marrow failure: A concise clinical review1
Germline predisposition to myeloid neoplasms: Characteristics and management of high versus variable penetrance disorders1
Accelerated and blast phase myeloproliferative neoplasms1
Targeted cellular therapy for treatment of relapsed or refractory leukemia1
The analysis of multiple outcomes, multiple variables and variables selection in hematopoietic cell transplantation studies1
Recent progress in acute leukemia and myelodysplasia1
Risk assessment and primary prevention of VTE in patients with cancer: Advances, challenges, and evidence gaps1
A reflection on Arnold Caplan, the father of MSC1
Biology and clinical management of hypoplastic MDS: MDS as a bone marrow failure syndrome1
Using real-world evidence in haematology1
Somatic mosaicism in inherited bone marrow failure syndromes1
Advances in polycythemia vera and lessons for acute leukemia1
A review of latest clinical practice guidelines for the management of cancer-associated thrombosis1
Blood coagulation and cancer genes1
Improving clinical trials in higher-risk myelodysplastic syndromes1
Editorial Board / Aims & Scope1
Diagnosis and management of lymphoblastic lymphoma in children, adolescents and young adults1
Cytogenetics in haematology1
Diagnosis and management of post-transplant lymphoproliferative disease following solid organ transplantation in children, adolescents, and young adults1
Editorial Board1
Editorial Board1
The landscape of cytogenetic and molecular genetic methods in diagnostics for hematologic neoplasia1
It is time to shift the treatment paradigm in myelodysplastic syndromes: A focus on novel developments and current investigational approaches exploring combinatorial therapy in high-risk MDS1
Cardiac surgery for radiation associated heart disease in Hodgkin lymphoma patients1
0.68277311325073